Register

Contact us

Home Fangda represented FountainVest Partners in its acquisition of 100% of the equity interests in Langdi Pharmaceutical, involving a transaction price of RMB5.8 billion

The press releases published in this section have been uploaded by law firms. Their content has not been appraised or edited by Law.asia, and no responsibility is taken for the accuracy of the information they contain or any misrepresentation therein. For our independent editorial content, please visit our homepage.

Fangda represented FountainVest Partners in its acquisition of 100% of the equity interests in Langdi Pharmaceutical, involving a transaction price of RMB5.8 billion

: Description

Fangda represented FountainVest Partners in its acquisition of 100% of the equity interests in Beijing Zhendong Langdi Pharmaceutical Co., Ltd (“Langdi Pharmaceutical”), involving a transaction price of RMB5.8 billion. The transaction was signed on August 17, 2021 and closed on October 29, 2021. Acting as the legal counsel to FountainVest Partners, Fangda handled the legal due diligence of Langdi Pharmaceutical and its subsidiaries, documentation and negotiation of the transaction documents, the closing process, and the debt financing of this transaction. The Fangda team on this deal was led by corporate partners Su Wang and Patrick Li, and banking partner Rock Wang, and the team members include Jason Zhao, Katherine Huang, Ray Xu, Patrick Peng, Synne Li and Kristen Sun. Langdi Pharmaceutical is a modern pharmaceutical company engaged in the production and sales of drugs and dietary supplements.